research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
Search
for
Sort by
Research
210-240 / 863 results 
research Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
research Baricitinib as a treatment for myasthenia gravis: A case report
Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
research Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Dysregulation of Leukaemia Inhibitory Factor (LIF) Signalling Pathway by Supraphysiological Dose of Testosterone in Female Sprague Dawley Rats During Development of Endometrial Receptivity
High testosterone levels can harm fertility by disrupting the LIF signaling pathway in the uterus.
research Poster Presentations
Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
Upadacitinib effectively treats psoriasiform eczema and some related conditions.
research Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Oclacitinib Treatment and Surgical Management in a Case of Periocular Eosinophilic Furunculosis and Vasculitis with Secondary Eyelid Fusion in a Diabetic Cat
Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.
research Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Advances in Vitiligo Treatment
Vitiligo treatment requires a personalized mix of therapies to restore skin color and improve life quality.
research Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
New treatments for alopecia show promise in restoring hair growth by targeting immune and hormonal factors.
research Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
research Deciphering the Complex Immunopathogenesis of Alopecia Areata
Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.
research Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders
The immune processes causing VKH and vitiligo are similar in dogs and humans.
research Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
research The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
research The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK /STAT inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.